Latest Us Healthcare Market News

Adherium Limited’s iCARE study reports unprecedented medication adherence improvements and sustained patient engagement in COPD and asthma care, highlighting significant clinical and economic benefits.

dorsaVi has inked a five-year sales agreement with Select Medical, opening access to over 1,900 US outpatient physical therapy centers for its FDA-approved motion analysis products. This follows a successful 18-month pilot validating clinical benefits in athlete rehabilitation.

Singular Health Group reported a $6.38 million loss for FY2025 while securing a pivotal $1.3 million commercial agreement with US-based Provider Network Solutions to deploy its 3DICOM software. The company also completed a major cloud migration of its platform, positioning itself for growth in the US healthcare market.

Micro-X Limited reported a $13.9 million loss for FY2025 as it pivots towards medical imaging, securing a landmark supply agreement with a major US healthcare provider for its Rover Plus mobile X-ray system.

Atomo Diagnostics has successfully placed $416,611.77 from its Share Purchase Plan shortfall, bolstered by a recent US order from Lumos Diagnostics. This capital injection strengthens Atomo’s position as it scales up production of its Pascal cassettes.

4DMedical has landed a $10 million strategic investment from Pro Medicus, aimed at accelerating its commercial growth and advancing its CT – VQ™ technology towards FDA clearance in the US.

Micro-X has landed a significant supply agreement with a top US healthcare provider for its Rover Plus mobile X-ray units, while progressing clinical trials and development milestones for its innovative CT imaging products.

Oneview Healthcare reported a €4 million cash outflow in Q2 2025, driven by restructuring and lower R&D credits, while securing new US hospital contracts and expanding AI-powered care solutions.

PainChek has completed its final FDA submission for the PainChek Adult App, targeting the US long-term care market with a potential $100 million annual opportunity. A regulatory decision is expected within 75 days, setting the stage for rapid commercialisation.

Lumos Diagnostics has inked a landmark six-year exclusive distribution agreement with PHASE Scientific for its FebriDx® rapid diagnostic test in the US, potentially unlocking nearly half a billion Australian dollars in revenue contingent on FDA approval.

Echo IQ has initiated a pivotal clinical validation study with the Mayo Clinic Platform to test its EchoSolv HF software, marking the final step before its planned FDA submission in late 2025.

Vitasora Health has expanded its partnership with The Physician Alliance Corporation from a pilot to a multi-year value-based care contract covering up to 15,000 Medicare patients, unlocking significant new revenue streams tied to patient outcomes.